| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2012 ( Subtotal = -$201,839 ) |
| | 2012 | 2010 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | K01CA113779 | DEVELOPMENT OF NOVEL MARKERS FOR MELANOMA PROGRESSION | 000 | 6 | NIH | 1/10/2012 | -$22,439 |
| | 2012 | 2010 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA121118 | A High-Throughput Model for Human Melanoma | 000 | 4 | NIH | 12/20/2011 | -$179,400 |
|
| Issue Date FY: 2011 ( Subtotal = $326,066 ) |
| | 2011 | 2011 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA133797 | DESIGN OF THERAPEUTIC STRATEGIES SPECIFIC FOR BREAST CANCER INITIATING CELLS | 001 | 5 | NIH | 5/13/2011 | $23,531 |
| | 2011 | 2011 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA133797 | DESIGN OF THERAPEUTIC STRATEGIES SPECIFIC FOR BREAST CANCER INITIATING CELLS | 000 | 5 | NIH | 1/12/2011 | $302,535 |
| | 2011 | 2008 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R21CA122270 | EPIGENETIC POTENTIATION OF INTERFERON USING DECITABINE | 000 | 2 | NIH | 2/4/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $525,483 ) |
| | 2010 | 2010 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01HL087948 | A MODEL OF MYELODYSPLASTIC SYNDROME PROGRESSION AND LEUKEMIC STEM CELLS | 003 | 3 | NIH | 8/13/2010 | -$94,044 |
| | 2010 | 2010 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01HL087948 | A MODEL OF MYELODYSPLASTIC SYNDROME PROGRESSION AND LEUKEMIC STEM CELLS | 000 | 3 | NIH | 12/7/2009 | $450,000 |
| | 2010 | 2010 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01HL087948 | A MODEL OF MYELODYSPLASTIC SYNDROME PROGRESSION AND LEUKEMIC STEM CELLS | 000 | 3 | NIH | 12/7/2009 | $100,800 |
| | 2010 | 2010 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA133797 | DESIGN OF THERAPEUTIC STRATEGIES SPECIFIC FOR BREAST CANCER INITIATING CELLS | 003 | 4 | NIH | 2/1/2010 | $336,150 |
| | 2010 | 2010 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA121118 | A High-Throughput Model for Human Melanoma | 000 | 4 | NIH | 1/21/2010 | $189,600 |
| | 2010 | 2010 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | K01CA113779 | DEVELOPMENT OF NOVEL MARKERS FOR MELANOMA PROGRESSION | 000 | 6 | NIH | 6/8/2010 | $156,426 |
| | 2010 | 2010 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01HL087948 | A MODEL OF MYELODYSPLASTIC SYNDROME PROGRESSION AND LEUKEMIC STEM CELLS | 003 | 3 | NIH | 8/13/2010 | -$412,595 |
| | 2010 | 2009 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01HL087948 | A MODEL OF MYELODYSPLASTIC SYNDROME PROGRESSION AND LEUKEMIC STEM CELLS | 002 | 2 | NIH | 8/13/2010 | $0 |
| | 2010 | 2009 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R21CA131522 | FLEXIBLE AND SOMATIC MOUSE MODELS FOR MYELODYSPLASTIC SYNDROME PROGRESSION | 000 | 2 | NIH | 5/6/2010 | -$184,505 |
| | 2010 | 2009 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA133797 | DESIGN OF THERAPEUTIC STRATEGIES SPECIFIC FOR BREAST CANCER INITIATING CELLS | 001 | 3 | NIH | 1/19/2010 | $211,324 |
| | 2010 | 2009 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01HL087948 | A MODEL OF MYELODYSPLASTIC SYNDROME PROGRESSION AND LEUKEMIC STEM CELLS | 001 | 2 | NIH | 7/9/2010 | -$227,673 |
| | 2010 | 2008 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R21CA122270 | EPIGENETIC POTENTIATION OF INTERFERON USING DECITABINE | 000 | 2 | NIH | 6/16/2010 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $1,700,448 ) |
| | 2009 | 2009 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA121118 | A High-Throughput Model for Human Melanoma | 001 | 3 | NIH | 3/20/2009 | $18,960 |
| | 2009 | 2009 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA121118 | A High-Throughput Model for Human Melanoma | 003 | 3 | NIH | 5/29/2009 | $208,080 |
| | 2009 | 2009 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | K01CA113779 | DEVELOPMENT OF NOVEL MARKERS FOR MELANOMA PROGRESSION | 002 | 5 | NIH | 6/25/2009 | $155,802 |
| | 2009 | 2009 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01HL087948 | A MODEL OF MYELODYSPLASTIC SYNDROME PROGRESSION AND LEUKEMIC STEM CELLS | 002 | 2 | NIH | 8/25/2009 | $26,550 |
| | 2009 | 2009 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R21CA131522 | FLEXIBLE AND SOMATIC MOUSE MODELS FOR MYELODYSPLASTIC SYNDROME PROGRESSION | 000 | 2 | NIH | 6/26/2009 | $243,000 |
| | 2009 | 2009 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01HL087948 | A MODEL OF MYELODYSPLASTIC SYNDROME PROGRESSION AND LEUKEMIC STEM CELLS | 000 | 2 | NIH | 12/3/2008 | $450,000 |
| | 2009 | 2009 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA121118 | A High-Throughput Model for Human Melanoma | 000 | 3 | NIH | 1/16/2009 | $170,640 |
| | 2009 | 2009 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01HL087948 | A MODEL OF MYELODYSPLASTIC SYNDROME PROGRESSION AND LEUKEMIC STEM CELLS | 001 | 2 | NIH | 7/30/2009 | $288,508 |
| | 2009 | 2008 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | K01CA113779 | DEVELOPMENT OF NOVEL MARKERS FOR MELANOMA PROGRESSION | 001 | 4 | NIH | 2/6/2009 | $138,908 |
|
| Issue Date FY: 2008 ( Subtotal = $1,627,546 ) |
| | 2008 | 2008 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R21CA122270 | EPIGENETIC POTENTIATION OF INTERFERON USING DECITABINE | 000 | 2 | NIH | 8/12/2008 | $226,328 |
| | 2008 | 2008 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA098955 | REGULATION OF REPLICATION CHECKPOINT BY PROTEOLYSIS | 000 | 6 | NIH | 5/23/2008 | $252,001 |
| | 2008 | 2008 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA121118 | A High-Throughput Model for Human Melanoma | 000 | 2 | NIH | 1/28/2008 | $189,600 |
| | 2008 | 2008 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R21CA131522 | FLEXIBLE AND SOMATIC MOUSE MODELS FOR MYELODYSPLASTIC SYNDROME PROGRESSION | 000 | 1 | NIH | 6/25/2008 | $202,500 |
| | 2008 | 2008 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01HL087948 | A MODEL OF MYELODYSPLASTIC SYNDROME PROGRESSION AND LEUKEMIC STEM CELLS | 000 | 1 | NIH | 12/14/2007 | $450,000 |
| | 2008 | 2008 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA102121 | ROLE OF URIDINE PHOSPHORYLASE IN CANCER TREATMENT | 000 | 6 | NIH | 2/12/2008 | $307,117 |
|
| Issue Date FY: 2007 ( Subtotal = $998,122 ) |
| | 2007 | 2007 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA098955 | REGULATION OF REPLICATION CHECKPOINT BY PROTEOLYSIS | 000 | 5 | NIH | 8/29/2007 | $228,250 |
| | 2007 | 2007 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R21CA122270 | EPIGENETIC POTENTIATION OF INTERFERON USING DECITABINE | 000 | 1 | NIH | 9/7/2007 | $243,677 |
| | 2007 | 2007 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA102121 | ROLE OF URIDINE PHOSPHORYLASE IN CANCER TREATMENT | 000 | 5 | NIH | 2/26/2007 | $297,095 |
| | 2007 | 2007 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA121118 | A High-Throughput Model for Human Melanoma | 000 | 1 | NIH | 4/13/2007 | $229,100 |
|
| Issue Date FY: 2006 ( Subtotal = $287,904 ) |
| | 2006 | 2006 | NEVADA CANCER INSTITUTE | 1000 WEST CHARLESTON BOULEVARD | LAS VEGAS | NV | 89135 | CLARK | USA | R01CA102121 | ROLE OF URIDINE PHOSPHORYLASE IN CANCER TREATMENT | 000 | 4 | NIH | 9/28/2006 | $287,904 |
|
|
